Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings.

Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J.

Arch Gen Psychiatry. 2001 Oct;58(10):901-6.

PMID:
11576026
2.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
3.

Neuroimaging research in human MDMA users: a review.

Cowan RL.

Psychopharmacology (Berl). 2007 Jan;189(4):539-56. Epub 2006 Jul 18. Review.

PMID:
16847678
4.

Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects.

Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ.

J Psychopharmacol. 2006 Mar;20(2):164-75. Review.

PMID:
16510475
5.
6.

(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals.

Ricaurte GA, Yuan J, McCann UD.

Neuropsychobiology. 2000;42(1):5-10. Review.

PMID:
10867550
7.

Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').

Ricaurte GA, McCann UD, Szabo Z, Scheffel U.

Toxicol Lett. 2000 Mar 15;112-113:143-6. Review.

PMID:
10720723
8.

3,4-methylenedioxymethamphetamine (MDMA): current perspectives.

Meyer JS.

Subst Abuse Rehabil. 2013 Nov 21;4:83-99. doi: 10.2147/SAR.S37258. eCollection 2013. Review.

9.

[Recent abuse of 3,4-methylenedioxymethamphetamine ("yaoto-wang", "ecstasy")].

Satsumi YN.

Seishin Shinkeigaku Zasshi. 2002;104(10):819-33. Review. Japanese.

PMID:
12607923
10.

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Vegting Y, Reneman L, Booij J.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3473-501. doi: 10.1007/s00213-016-4396-5. Epub 2016 Aug 28. Review.

11.

Neurotoxicity of drugs of abuse--the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines.

Gouzoulis-Mayfrank E, Daumann J.

Dialogues Clin Neurosci. 2009;11(3):305-17. Review.

12.

Brain serotonin function in MDMA (ecstasy) users: evidence for persisting neurotoxicity.

Benningfield MM, Cowan RL.

Neuropsychopharmacology. 2013 Jan;38(1):253-5. doi: 10.1038/npp.2012.178. Review. No abstract available. Erratum in: Neuropsychopharmacology. 2013 Apr;38(5):907.

13.

Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users.

Roberts CA, Jones A, Montgomery C.

Neurosci Biobehav Rev. 2016 Apr;63:158-67. doi: 10.1016/j.neubiorev.2016.02.003. Epub 2016 Feb 6. Review.

14.

[Minocycline as a therapeutic drug for methamphetamine use disorders].

Hashimoto K.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 Feb;28(1):19-22. Review. Japanese.

PMID:
18411705
15.

Imaging the neurochemistry of alcohol and substance abuse.

Martinez D, Kim JH, Krystal J, Abi-Dargham A.

Neuroimaging Clin N Am. 2007 Nov;17(4):539-55, x. Review.

PMID:
17983969

Supplemental Content

Support Center